We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Inspection of API Manufacturer in China Shows Nonexistent QC Documentation
Inspection of API Manufacturer in China Shows Nonexistent QC Documentation
Following on the heels of a House subcommittee meeting to discuss FDA inspections of foreign drug manufacturers, the FDA released a scathing 483 inspection report of an active pharmaceutical ingredient (API) manufacturer in China.